8 Tips for taking control of your blood pressure
The best way to slow the progression of IgA Nephropathy from high blood pressure is to take steps to control it. 1: Take your medicine every day as directed Most …
Improving Patient-Provider Communications in IgA Nephropathy.
We want to tell you about an important research collaboration between IgA Nephropathy Foundation and the National Kidney Foundation (NKF). This research will have two phases. First, separate surveys of …
IgAN Cookbook and Aware Day Press Release
The IgA Nephropathy Foundation Launches First-Ever Cookbook Ahead of IgAN Awareness Day The Second Annual ‘IgAN Aware Day’ brings attention to the need for earlier diagnosis and treatments; cookbook offers …
6 Tips for Doing Your Own Research
It’s hard not to want to do your own research after learning you have a health condition like IgA Nephropathy. And while you should feel empowered to do your own …
Thinking About What You Want From Treatment
When it comes to making a treatment decision for IgA Nephropathy, focusing on your priorities is important. Asking yourself “What do I most want to achieve from treatment?”, “How will …
Understanding Your Treatment Options
Factors that can shape treatment decisions Your provider might use a calculator of sorts to plug in information and help determine how quickly your condition may progress. This can also …
IgA Nephropathy Foundation Announces Launch of Medical and Scientific Advisory Board
May 25, 2022 – The IgA Nephropathy Foundation (IGAN Foundation), a nonprofit dedicated to supporting patients with a rare autoimmune kidney disease called IgA Nephropathy, today announced its formation of …
Igan Basics
There is a lot of technical language around IgAN and it can seem confusing and overwhelming when receiving a diagnosis for yourself or a loved one. You may have many …
National Kidney Foundation’s and IgA Nephropathy Foundation’s Externally-Led Patient Focused Drug Development (EL-PFDD) Meeting on IgA Nephropathy
The NKF and IGANF conducted an EL-PFDD meeting on IgAN to inform the FDA on the patient perspective on living with this disease. Understanding the patient perspective will help the …
Ten Years Follow-up of STOP-IgAN Trial
Abstract The randomized, controlled STOP-IgAN trial in patients with IgA nephropathy (IgAN) and substantial proteinuria showed no benefit of immunosuppression added on top of supportive care on renal function over …
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
Abstract IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course …